Media Releases
View the latest media releases and news stories from Lilly Australia and New Zealand.
Lilly named Excellence Awardee in the Australian HR Awards for the fourth year running
1 July 2024 - Eli Lilly Australia and New Zealand (Lilly) has been recognised as a finalist and shortlisted as an Excellence Awardee in the ‘Employer of Choice (100-999 employees)’ category at the prestigious annual Australian HR Awards. Lilly’s submission delved into the company’s acknowledgment of the need for structural, cultural and personnel change to maximise the value of its current and emerging portfolio and deliver on the company’s purpose.
View Media Release
Lilly named Excellence Awardee in the Australian HR Awards for Best Remote Work Strategy
19 June 2023 - Eli Lilly Australia and New Zealand (Lilly) has been shortlisted as an Excellence Awardee in the ‘Best Remote Work Strategy’ category at the prestigious annual Australian HR Awards. This award recognises excellence in virtual and remote work programs and practices and is judged on level of innovation, employee engagement, productivity and results.
View Media Release
Australian specialists want top 5 OECD ranking for medicines access
15 May 2023 - According to The Medicines Waiting Room research commissioned by Eli Lilly Australia medical specialists believe Australia would benefit from faster, more efficient medicine funding processes, easing of eligibility criteria for reimbursed therapies, greater clinician input to reimbursement decision-making, and Government efforts to shore up supply of reimbursed medicines.
View Media Release
Lilly Australia moves to Sydney CBD
2 March 2023 - Yesterday, Eli Lilly Australia (Lilly) employees were welcomed into their new premises at Level 9, 60 Margaret Street, Sydney. The company has relocated from its West Ryde location, which has been its home since commencing operations in Australia in 1960.
View Media Release
Lilly ANZ announces incoming GM
11 October 2022 - Eli Lilly (Lilly) has today announced that Benjamin Basil, President of North Asia-Pacific and General Manager of Australia and New Zealand will soon assume a new role as the President and General Manager of Eli Lilly China. Tori Brown, General Manager of Eli Lilly Switzerland will succeed Benjamin.
View Media Release
Lilly named a finalist in the Australian HR Awards for the second year running
27 June 2022- For the second year running Eli Lilly Australia & New Zealand (Lilly) has been shortlisted as an Excellence Awardee in the prestigious annual Australian HR Awards.
View Media Release
Lilly named a finalist in two categories at the Australian HR Awards
15 June 2021- Eli Lilly Australia & New Zealand has been shortlisted as an Excellence Awardee in two categories at the prestigious annual Australian HR Awards.
View Media Release
Lilly Unleashes the Power of Generational Diversity
9 June 2021-The Generation Diversity, Inclusion and Equity Group at Eli Lilly Australia & New Zealand (Lilly ANZ) aims to embrace and celebrate generational diversity to ensure employees from all generations feel their experiences, perspectives and ideas are valued.
View Media Release
Lilly Ranks No. 3 for the Second Year in DiversityInc's Top 50
18 May 2021- For the second year in a row, Lilly has been ranked third in DiversityInc’s list of Top 50Companies for Diversity. DiversityInc Top 50 list is issued annually and recognises top companies for diversity and inclusion management.
View Media Release
TRULICITY® (dulaglutide) in combination with insulin is now available on the PBS for Australians with type 2 diabetes
1 March 2021- Eli Lilly Australia is pleased to announce that dulaglutide (TRULICITY®) is now reimbursed under the Pharmaceutical Benefits Scheme (PBS) for concomitant use with insulin for patients with type 2 diabetes (T2D).
View Media Release
TRULICITY® (dulaglutide) is now indicated in adults with type 2 diabetes to reduce the risk of Major Adverse Cardiovascular Events (MACE) in patients with multiple risk factors for, or established, cardiovascular disease.
12 August 2020 - Eli Lilly Australia welcomes the Therapeutic Goods Administration’s (TGA) acceptance of the expanded label indication for TRULICITY® (dulaglutide).
View Media Release
PP-MG-AU-0121 07/2024